What is Zacks Research's Forecast for A FY2025 Earnings?

Key Points

• Analysts at Zacks Research have revised their FY2025 earnings estimate for Agilent Technologies to $5.57 per share, down slightly from their previous forecast of $5.58.
• Several firms have updated their target prices for Agilent, with Wells Fargo raising it to $140, while UBS Group reduced it to $130.
• The company's stock has a current market capitalization of $34.92 billion and an average rating of "Moderate Buy" with a price target of $139.25 from analysts.

Agilent Technologies, Inc. (NYSE:A - Free Report) - Analysts at Zacks Research lowered their FY2025 earnings estimates for Agilent Technologies in a report released on Friday, September 12th. Zacks Research analyst Team now expects that the medical research company will earn $5.57 per share for the year, down from their prior forecast of $5.58. The consensus estimate for Agilent Technologies' current full-year earnings is $5.58 per share. Zacks Research also issued estimates for Agilent Technologies' Q4 2025 earnings at $1.58 EPS, Q1 2026 earnings at $1.38 EPS, Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.48 EPS, Q4 2026 earnings at $1.66 EPS, FY2026 earnings at $5.91 EPS, Q1 2027 earnings at $1.56 EPS, Q2 2027 earnings at $1.55 EPS, Q3 2027 earnings at $1.63 EPS and FY2027 earnings at $6.49 EPS.

A number of other research firms have also recently commented on A. Wells Fargo & Company increased their target price on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. UBS Group reduced their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research note on Thursday, May 29th. TD Cowen boosted their price target on shares of Agilent Technologies to $150.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Barclays reissued an "equal weight" rating and issued a $125.00 price objective on shares of Agilent Technologies in a research note on Friday, August 29th. Finally, Leerink Partners upped their price target on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $139.25.

Agilent Technologies Trading Down 2.8%

Shares of A opened at $123.19 on Monday. Agilent Technologies has a 12-month low of $96.43 and a 12-month high of $153.84. The firm has a market capitalization of $34.92 billion, a price-to-earnings ratio of 28.92, a P/E/G ratio of 3.83 and a beta of 1.24. The stock's 50-day moving average price is $119.76 and its 200 day moving average price is $115.79. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the prior year, the company posted $1.32 earnings per share. The firm's quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Institutional Trading of Agilent Technologies

Several institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in Agilent Technologies by 13.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after buying an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Agilent Technologies by 8.3% during the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the period. Alps Advisors Inc. raised its stake in Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after acquiring an additional 3,040 shares in the last quarter. D.A. Davidson & CO. raised its position in shares of Agilent Technologies by 30.4% during the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock worth $1,108,000 after purchasing an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. boosted its stake in shares of Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock worth $89,870,000 after acquiring an additional 54,302 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.